Press Release Summary:
- Used for the quantitative determination of β-ketones and glucose in whole blood taken from capillary or venous samples
- Results are displayed on a large LCD screen interface with capacity for up to 400 measurements to be stored on the system
- Auto-starts when a test strip is inserted and will also automatically detect if it is a BHB or glucose test to be undertaken
Original Press Release:
EKF Globally Launches STAT-Site® WB β-ketone and Glucose Handheld Analyzer
EKF obtains CE mark certification alongside CLIA waiver for easy-to-use whole blood analyzer for diabetes care programs
Cardiff, UK – 11th March 2021 – EKF Diagnostics, the global in vitro diagnostics company, announces the global launch of its STAT-Site® WB handheld analyzer which delivers β-ketone and glucose measurements from whole blood in seconds. This follows the securing of its CE mark certification alongside its FDA CLIA-waiver, meaning that the portable, dual-purpose analyzer is ideal for professional use in the management of diabetes patients.
The STAT-Site® WB is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or BHB) and glucose in whole blood taken from capillary or venous samples. The easy-to-use analyzer is reagent free, utilizing two different test strips to deliver results in just 10 seconds for β-ketones and 5 seconds for glucose. This enables clear and comprehensive management of diabetes patients displaying early symptoms of ketosis, ensuring their rapid treatment and subsequent regular monitoring.
βHB is used to aid the diagnosis and monitoring of patients with ketosis (diabetic ketoacidosis or DKA). As β-HB accounts for 78% of all ketones present in the body, and is the first to appear during ketosis, it provides the clearest indication of a patient’s condition before and after treatment. The STAT-Site WB is calibrated to the gold standard Liquicolor Beta-Hydroxybutyrate method, meaning that it delivers laboratory accurate results within seconds near to the patient.
Further ensuring results accuracy, the handheld analyzer is simple and intuitive to use, even for inexperienced users. The STAT-Site WB auto-starts when a test strip is inserted and will also automatically detect if it is a BHB or glucose test to be undertaken. Just 1 µL of whole blood is required for direct analysis and the system will also detect and alert if insufficient blood is available. An automatic strip ejection function ensures that cross contamination is avoided.
Also making it ideal for remote testing, the analyzer uses two 1.5V AAA alkaline batteries which are easy to obtain and replace, whilst test strips are available individually foil wrapped or in a vial with a shelf life of six months once opened. Results are clearly displayed on a large LCD screen interface with capacity for up to 400 measurements to be stored on the system – these can be downloaded via a mini USB lead.
“STAT-Site WB provides an affordable, easy-to-use technology that can help to reduce the cost of long-term healthcare of the growing diabetic and pre-diabetic population globally,” said Gavin Jones, Head of Product Management, EKF Diagnostics. “Having direct access to lab quality β-ketone and glucose near patient results ensures the practitioner has the essential data needed to make informed clinical or lifestyle decisions in seconds.”
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, Stanbio Laboratory and DiaSpect brands, specializes in the development, production and worldwide distribution of point-of-care analyzers for use in the detection and management of diabetes and anemia, and also in sports and maternal medicine. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents, as well as associated analyzers. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
COVID-19 testing: EKF also sells a range of COVID-19 testing products, including: PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under license; and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise quantitative measurement of COVID-19 IgG antibodies.